Why a cheap patent transfer did not reset insulin prices
A patent is only one part of the system that determines what patients pay. Selling a patent for a nominal amount does not automatically create a low-priced medicine: a company still needs to manufacture insulin, obtain regulatory approval, and arrange for pharmacies and insurers to make it available. Nor does a change in ownership erase other patents or the market arrangements built around a product.
Insulin is a biologic—a medicine made using living cells—so making a close substitute and proving it meets regulatory standards is more complicated than copying many small-molecule drugs. Manufacturers can also seek patents on later changes to a product or its delivery system. Those patents may protect particular improvements, but they can also make it harder for competing versions to enter. The result is that a single patent sale need not open the market to immediate competition.
How rebates can keep the sticker price elevated
In the U.S. system, pharmacy-benefit managers, or PBMs, negotiate with drugmakers on behalf of health plans. A manufacturer may offer a rebate in exchange for favorable insurance coverage, such as placement on a plan’s formulary—the list of medicines the plan covers. This can help a medicine win access to patients, but it also creates a pricing tension: negotiations may revolve around a drug’s list price and the rebate tied to it, rather than simply pushing that list price down.
The rebate does not necessarily reach the person picking up insulin. If a patient’s cost is based on the list price, especially before a deductible is met or under coinsurance, a lower net price received by the plan may not mean a lower payment at the pharmacy counter. Plans and intermediaries may benefit from negotiated discounts while some patients remain exposed to the higher starting price.
The gap between making insulin and paying for it
Manufacturing cost is only one component of the final bill. Patent protections can limit competition, while rebate-based negotiations can reward discounts off a high list price instead of transparent, upfront reductions. That is why insulin can cost far less to produce than a patient’s bill suggests—and why lowering production costs alone would not necessarily make it affordable.
